Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology
Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology
Recruiting · NCT06378190 · Registry updated 2026-04-16Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-04-16 | NCT06378190 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Clínica Universidad de Navarra | Pamplona | Spain | 16 |
| Fundación Jiménez Díaz Hospital | Madrid | Spain | 1 |
| Hospital Clínic | Barcelona | Spain | 4 |
| Institut Català d'Oncologia Hospital | L'Hospitalet de Llobregat | Spain | 1 |
| Salamanca University Health Care Complex | Salamanca | Spain | 1 |
| University Hospital of Navarra | Pamplona | Spain | 1 |
| Virgen de la Arrixaca University Hospital | El Palmar | Spain | 1 |
| Virgen del Rocio Hospital | Seville | Spain | 1 |